October 28, 2019 11:00 AM EDTUpdated October 29, 04:55 AM
Pharma
FDA+

Al­ler­gan ties up Na­men­da loose ends with $750M set­tle­ment

Natalie Grover

Reporter

Al­ler­gan, which is in process of be­ing swal­lowed by Ab­b­Vie, is clear­ing out the cob­webs. On Mon­day, it agreed to pay $750 mil­lion to …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Global Head of Marketing

Bachem

Bubendorf, BL, Switzerland

TRENDING NOW

Roche no longer wants to be where ‘DNA se­quenc­ing goes to die’

Kevin Tang's Con­cen­tra tries to dis­rupt pro­posed Ace­lyrin-Alu­mis merg­er

Trump’s HHS de­fends drug price ne­go­ti­a­tions in No­var­tis suit

Pfiz­er ends roll­out of Be­qvez, putting an­oth­er dent in he­mo­phil­ia gene ther­a­py field

First meet­ing of CDC vac­cine ad­vi­sors in the Kennedy era is post­poned

sponsored

Trust­ed pro­tec­tion: Why the cur­rent meningo­coc­cal vac­ci­na­tion sched­ule shouldn’t change with­out strong ev­i­dence

A service from the Financial Times